RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Humacyte, an innovator in biotechnology and regenerative medicine, was selected among hundreds of candidates as one of the World Economic Forum’s 30 “Technology Pioneers”, a selection of the world’s most innovative companies. Humacyte is a medical research, discovery and development company with clinical and pre-clinical stage investigational products having potential therapeutic applications across illnesses such as end-stage renal disease, repair or replacement of damaged arteries, coronary artery bypass surgery, and vascular trauma.
The World Economic Forum’s Technology Pioneers community are companies from around the world that are involved in the design, development and deployment of new technologies and innovations, and are poised to have a significant impact on business and society. The 30 Technology Pioneers are active in artificial intelligence, augmented reality, autonomous vehicles, biotechnology, blockchain, cybersecurity, the (industrial) internet of things, and other revolutionary technologies.
Following its selection as a Technology Pioneer, Humacyte will be honored during the World Economic Forum Annual Meeting of the New Champions, dubbed “Summer Davos”, being held in Dalian, China, June 27-29. Many Pioneers will also attend the World Economic Forum’s Annual Meeting in Davos, in January 2018, and continue to participate in dedicated Technology Pioneer community events in the course of the next two years.
“We welcome Humacyte in this group of extraordinary pioneers,” commented Fulvia Montresor, Head of Technology Pioneers at the World Economic Forum. “We hope that thanks to this selection, the World Economic Forum can facilitate greater collaboration with business leaders, governments, civil society and other relevant individuals to accelerate the development of technological solutions to the world’s greatest challenges.”
“The brilliant minds, breakthrough technology, and passionate team at Humacyte have led the company to this extraordinary recognition, and we are honored to be chosen by the World Economic Forum as a Technology Pioneer,” said Carrie S. Cox, Chairman and Chief Executive Officer of Humacyte. “Keeping patient care at its core, Humacyte’s scientific discoveries are designed to create ‘off-the-shelf,’ or ready to use, bioengineered blood vessels. Today these conduits are being investigated clinically for patients undergoing kidney dialysis who require vascular access and for patients with peripheral arterial disease. However, this technology may be extended into a range of vascular applications in the future, with the potential for better clinical outcomes and lower healthcare costs. Our vision is to make a meaningful impact in healthcare by advancing innovation in regenerative medicine to produce life-sustaining improvements for patients with vascular disease.”
The Technology Pioneers were chosen by a selection committee of more than 60 academics, entrepreneurs, venture capitalists and corporate executives. Notable members of the committee include Geoffrey Moore (Adviser, Geoffrey Moore Consulting, USA), Yossi Vardi (Chairman, International Technologies, Israel) and Lee Sang-Yup (Distinguished Professor and Dean, Korea Advanced Institute of Science and Technology, Republic of Korea). The committee based its decisions on criteria including innovation, potential impact and leadership. Past recipients include Airbnb, Google, Kickstarter, Mozilla, Palantir Technologies, Scribd, Spotify, Twitter and Wikimedia.
Additional information about this year’s Technology Pioneers can be found here: http://wef.ch/techpioneers17
More information on past winners can be found here: http://www.weforum.org/community/technology-pioneers
Humacyte, Inc., a privately held company founded by Dr. Laura E. Niklason, M.D., Ph.D., in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.
All statements, other than statements of historical fact, included in this announcement are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “will”, “anticipate”, “expect”, “believe”, “intend” and “should” or the negative of these terms or other comparable terminology. These statements relate to future events or Humacyte’s clinical development programs, reflect management’s current beliefs and expectations and involve known and unknown risks, uncertainties and other factors that may cause Humacyte’s actual results, performance or achievements to be materially different. Except as required by law, Humacyte assumes no obligation to update these forward-looking statements.
About World Economic Forum:
The World Economic Forum, committed to improving the state of the world, is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business and other leaders of society to shape global, regional and industry agendas. (www.weforum.org).